Puma Biotechnology Presents Outcomes from the Metastatic Breast Cancer Cohort of the SUMMIT Trial at the ASCO 2022 Annual Meeting
Retrieved on:
Monday, June 6, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Lynx, ALT, Electrolyte, Constipation, Adult, Histology, Indigestion, Enzyme inhibitor, Antidiarrhoeal, Capecitabine, Nausea, HER3, CYP3A4, Fatigue, Abdominal pain, Food, Gastric acid, Puma Biotechnology, Arthralgia, Back pain, Dizziness, Upper respiratory tract infection, MBC, HER2, Appetite, FDA, Puma, Patient, Trastuzumab, Fetus, Kidney, Risk, Tablet, AST, Fulvestrant, Vomiting, Royal commission, Spasm, Diarrhea, Birth, Degenerative disease, Urinary tract infection, Stomatitis, European Commission, Transaminase, Rash, Fourth grade, Abdominal distension, Hepatotoxicity, Nosebleed, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Antacid, Neoplasm, Breast cancer classification, Safety, Pharmaceutical industry, Medical imaging, Vaccine
Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.
Key Points:
- Alan H. Auerbach, Chief Executive Officer, and President of Puma Biotechnology added, HER2 mutations can be readily and accurately identified and are clinically actionable for targeted therapy in metastatic breast cancers.
- We are very pleased with the updated activity seen with the combination of neratinib plus trastuzumab plus fulvestrant therapy in this heavily pretreated metastatic breast cancer patient population with HER2-mutated disease.
- Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care.
- Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.